Premium
F3‐03‐01: Disclosing ApoE genotype status to individuals at risk for Alzheimer's disease: Applying lessons learned from the reveal study to prevention treatment trials
Author(s) -
Roberts J. Scott,
Green Robert C.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.230
Subject(s) - disease , anxiety , apolipoprotein e , depression (economics) , clinical psychology , medicine , alzheimer's disease , randomized controlled trial , genetic testing , psychology , genetic counseling , distress , psychiatry , gerontology , genetics , biology , economics , macroeconomics
APOE-e4 carriership (MCI 41%, dementia 48%) was more frequent than in subjects with both biomarkers normal (MCI 26%, dementia 34%) but less frequent than in subjects with both biomarkers abnormal (MCI 70%, dementia 57%). Both MCI and demented subjects with SNAP had lower MMSE scores than subjects with normal biomarker scores but higher scores than subjects with both biomarkers abnormal. Conclusions: SNAP is common in subjects with MCI and dementia and is associated with age and APOE genotype. The high frequency of SNAP in elderly subjects with a clinical diagnosis of AD suggests that at high age clinical criteria may often not be specific for AD.